Clinical Trials
13 trialsNCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT07558447 2026-04-30
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase NA Recruiting
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02675829 2026-03-04
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT04544748 2024-03-06
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
Phase 1 Unknown
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed